WeVote
Log In

Bill

Bill

HR 7970

STOP Nitazenes Act

119th Congress Introduced by Jim Baird and 5 co-sponsors

Legislation to control nitazene opioids through scheduling, enforcement, and awareness to combat emerging synthetic drug threat in illicit supplies.

Subcommittee Consideration and Mark-up Session Held
0
WeVote Research Nonpartisan
Bill Summary · HR 7970

Legislative bill overview

HR 7970, the STOP Nitazenes Act, seeks to address the emerging public health threat posed by nitazene opioids—a class of synthetic drugs that have recently appeared in illicit drug supplies across the United States. The bill likely proposes scheduling or regulatory controls on nitazenes, along with enforcement and awareness measures to combat their distribution and use. This represents a legislative response to a drug threat that has gained attention from law enforcement and public health officials in recent years.

Why is this important

Nitazenes are potent synthetic opioids that have been detected in counterfeit pills and drug supplies, sometimes mixed with fentanyl or present alone, creating acute overdose risks for users who may be unaware of their presence. The emergence of this new drug class highlights evolving challenges in combating synthetic opioid threats and the need for regulatory frameworks to keep pace with clandestine drug manufacturing. Appropriate scheduling and enforcement could help slow distribution, while awareness efforts may reduce accidental exposure.

Potential points of contention

  • Scheduling concerns: Rapid scheduling of nitazenes could be viewed as necessary action or as reactive policy-making that doesn't address root causes of opioid addiction and supply-chain vulnerabilities
  • International coordination: Nitazenes are already controlled in some countries; the bill's effectiveness depends on coordinating with international partners to prevent workarounds or manufacturing shifts
  • Resource allocation: Implementation requires funding for enforcement, treatment, and public awareness—raising questions about prioritization amid existing drug policy efforts and budget constraints

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.